BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24803160)

  • 1. Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study.
    Michalopoulos SN; Kella N; Payne R; Yohannes P; Singh A; Hettinger C; Yousefi K; Hornberger J;
    Curr Med Res Opin; 2014 Aug; 30(8):1547-56. PubMed ID: 24803160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery.
    Badani KK; Thompson DJ; Brown G; Holmes D; Kella N; Albala D; Singh A; Buerki C; Davicioni E; Hornberger J
    BJU Int; 2015 Mar; 115(3):419-29. PubMed ID: 24784420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.
    Badani K; Thompson DJ; Buerki C; Davicioni E; Garrison J; Ghadessi M; Mitra AP; Wood PJ; Hornberger J
    Oncotarget; 2013 Apr; 4(4):600-9. PubMed ID: 23592338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study.
    Gore JL; du Plessis M; Santiago-Jiménez M; Yousefi K; Thompson DJS; Karsh L; Lane BR; Franks M; Chen DYT; Bandyk M; Bianco FJ; Brown G; Clark W; Kibel AS; Kim HL; Lowrance W; Manoharan M; Maroni P; Perrapato S; Sieber P; Trabulsi EJ; Waterhouse R; Davicioni E; Lotan Y; Lin DW
    Cancer; 2017 Aug; 123(15):2850-2859. PubMed ID: 28422278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists.
    Nguyen PL; Shin H; Yousefi K; Thompson DJ; Hornberger J; Hyatt AS; Badani KK; Morgan TM; Feng FY
    Urology; 2015 Jul; 86(1):35-40. PubMed ID: 26142578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.
    Den RB; Yousefi K; Trabulsi EJ; Abdollah F; Choeurng V; Feng FY; Dicker AP; Lallas CD; Gomella LG; Davicioni E; Karnes RJ
    J Clin Oncol; 2015 Mar; 33(8):944-51. PubMed ID: 25667284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy.
    Freedland SJ; Choeurng V; Howard L; De Hoedt A; du Plessis M; Yousefi K; Lam LL; Buerki C; Ra S; Robbins B; Trabulsi EJ; Shah NL; Abdollah F; Feng FY; Davicioni E; Dicker AP; Karnes RJ; Den RB
    Eur Urol; 2016 Oct; 70(4):588-596. PubMed ID: 26806658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy.
    Marascio J; Spratt DE; Zhang J; Trabulsi EJ; Le T; Sedzorme WS; Beeler WH; Davicioni E; Dabbas B; Lin DW; Gore JL; Bloom M; Mann M; Mark JR; Calvaresi A; Godwin JL; McCue P; Hurwitz MD; Kelly WK; Lallas CD; Knudsen KE; Gomella LG; Dicker AP; Den RB
    Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):295-302. PubMed ID: 31719663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.
    Howard LE; Zhang J; Fishbane N; Hoedt AM; Klaassen Z; Spratt DE; Vidal AC; Lin D; Hitchins MP; You S; Freeman MR; Yamoah K; Davicioni E; Freedland SJ
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):419-428. PubMed ID: 31844180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Karnes RJ; Choeurng V; Ross AE; Schaeffer EM; Klein EA; Freedland SJ; Erho N; Yousefi K; Takhar M; Davicioni E; Cooperberg MR; Trock BJ
    Eur Urol; 2018 Feb; 73(2):168-175. PubMed ID: 28400167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knowledge, attitudes and beliefs towards management of men with locally advanced prostate cancer following radical prostatectomy: an Australian survey of urologists.
    Brown B; Young J; Kneebone AB; Brooks AJ; Dominello A; Haines M
    BJU Int; 2016 Apr; 117 Suppl 4():35-44. PubMed ID: 25585989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer.
    Lobo JM; Trifiletti DM; Sturz VN; Dicker AP; Buerki C; Davicioni E; Cooperberg MR; Karnes RJ; Jenkins RB; Den RB; Showalter TN
    Clin Genitourin Cancer; 2017 Jun; 15(3):e299-e309. PubMed ID: 28089723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
    Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
    Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing attitudes towards management of men with locally advanced prostate cancer following radical prostatectomy: A follow-up survey of Australia-based urologists.
    Brown B; Egger S; Young J; Kneebone AB; Brooks AJ; Dominello A; Haines M
    J Med Imaging Radiat Oncol; 2016 Dec; 60(6):744-755. PubMed ID: 27346844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk.
    Ross AE; Den RB; Yousefi K; Trock BJ; Tosoian J; Davicioni E; Thompson DJ; Choeurng V; Haddad Z; Tran PT; Trabulsi EJ; Gomella LG; Lallas CD; Abdollah F; Feng FY; Klein EA; Dicker AP; Freedland SJ; Karnes RJ; Schaeffer EM
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):277-82. PubMed ID: 27136742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the Decipher genomic classifier among men with prostate cancer in the United States.
    Zaorsky NG; Proudfoot JA; Jia AY; Zuhour R; Vince R; Liu Y; Zhao X; Hu J; Schussler NC; Stevens JL; Bentler S; Cress RD; Doherty JA; Durbin EB; Gershman S; Cheng I; Gonsalves L; Hernandez BY; Liu L; Morawski BM; Schymura M; Schwartz SM; Ward KC; Wiggins C; Wu XC; Shoag JE; Ponsky L; Dal Pra A; Schaeffer EM; Ross AE; Sun Y; Davicioni E; Petkov V; Spratt DE
    JNCI Cancer Spectr; 2023 Aug; 7(5):. PubMed ID: 37525535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.